Reingard Senekowitsch-Schmidtke

TL;DR: First imaging results using a small animal positron emission tomograph suggest that this compound is suitable for noninvasive determination of the α v β 3 integrin status and therapy monitoring.

TL;DR: The high in vivo stability of L-FET, its fast brain and tumor uptake kinetics, its low accumulation in nontumor tissue and its ease of synthesis strongly support further evaluation of L-[18F]FET as an amino acid tracer for cerebral and peripheral tumors.

TL;DR: The synthesis and biological evaluation of the first glycosylated RGD-containing peptide (RGD-peptide) for the noninvasive imaging of alpha(v)beta3 expression demonstrates that the introduction of a sugar moiety improves the pharmakokinetic behavior of the peptide.

TL;DR: In vitro binding assays demonstrate that the introduction of tyrosine and subsequent iodination have no influence on the high affinity and selectivity for alpha(v)beta3, and the synthesis and biological evaluation of [125I]-3-iodo-D-Tyr4-cyclo(-Arg-Gly-Asp-D.Tyr-Val-) represents the first radiolabeled alpha( v) beta3 antagonist for the investigation of angiogenesis and metastasis

TL;DR: L-[18F]FET, which is transported by the specific amino acid transport system L, seems to be a potential amino acid tracer for tumor imaging and therapy monitoring with PET.